Xilio Therapeutics, Inc.
XLO
$8.46
-$0.05-0.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 163.61% | -2.80% | -19.44% | -1.31% | 6.61% |
| Total Depreciation and Amortization | -5.00% | -10.76% | -23.34% | 32.18% | -1.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -211.16% | 347.84% | 140.07% | 1.19% | -3.74% |
| Change in Net Operating Assets | 131.38% | -568.80% | -106.71% | 1,459.86% | -83.89% |
| Cash from Operations | 88.58% | -20.85% | -149.96% | 304.69% | -3.55% |
| Capital Expenditure | -- | 100.00% | -1,722.73% | -266.67% | 33.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -1,722.73% | -266.67% | 33.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -- | -100.00% | -99.09% | -41.09% | 204,950.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16,402.81% | -100.60% | -- | -- | -- |
| Cash from Financing | 12,684.56% | -100.60% | 880.17% | -41.09% | 273,500.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 289.95% | -154.73% | -3.86% | 666.82% | 56.44% |